Primary immune thrombocytopenia research hub
6 indexed studies · 2 currently recruiting
- ongoing, recruitingTherapeutic confirmatory (Phase III)
ARGX-113-1803: A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia
This study is looking at a new medicine called efgartigimod for adults with primary immune thrombocytopenia (ITP). It wants to see if the medicine is safe and how well it helps improve platelet counts over a long time. Researchers will check for side effects and how patients feel.
Italy · Czechia · Poland - recruitingPHASE2
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
This study looks at giving a second course of ianalumab to adults with certain blood conditions (ITP or wAIHA) if their first treatment worked but then stopped or wasn't enough. It's to see if a second round is safe and helps them again.
Belgium · China · Czechia - active not recruitingPHASE3
Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia
This study compares two treatments for newly diagnosed primary immune thrombocytopenia (ITP): romiplostim plus dexamethasone versus dexamethasone alone. Researchers want to see if combining these medicines works better at keeping platelet counts up and preventing bleeding over time.
Italy · Spain · United Kingdom - active not recruitingPHASE3
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
This study looks at a new injection called efgartigimod for adults with primary immune thrombocytopenia (ITP). It aims to see how safe and effective it is. If you've been in a previous study for this treatment, you might be able to continue.
United States · Argentina · Australia - active not recruitingPHASE3
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
This study is for adults with a blood condition called ITP who haven't improved with steroid treatment. It's testing a new drug called ianalumab, given with another drug called eltrombopag, to see if it can help keep blood platelet levels stable and safe for longer.
United States · Argentina · Austria - recruitingPHASE2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
This study is testing a new medicine called PF-06835375 for adults with a blood condition called Immune Thrombocytopenia (ITP). It aims to see if the medicine is safe and helps increase blood platelet counts in people who have had ITP for a few months or longer.
United States · Australia · Canada